Recent Updates
Recently added Catalysts

Ibuprofen Immediate Release/ Caplet

Phase 3

Analgesia | Small molecule | Pain |Pfizer, Inc.|Last Updated: Aug 28, 2017

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment1,083

FDA Designations

No designations recorded

Clinical trial landscape

Ibuprofen Immediate Release/ Caplet · 1 trial · 1 indication

Phase 3 1
NCT01789606Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended CapletAnalgesia
COMPLETED1,083 Analytics
PHASE3COMPLETED
Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet
AnalgesiaUnlock trial analytics

Study Endpoints

Primary Endpoints

Percentage of Participants Who Correctly Select to Use or Correctly De-select Not to Use Ibuprofen 600 Milligram (mg) Immediate Release (IR) or Extended Release (ER) Study Medication
Day 1

Participants as correct selectors included all participants who selected Ibuprofen 600 mg IR/ER medication with the last episode of pain of \>=6 hours, if left untreated. Participants as correct de-selectors included all participants who either selected Ibuprofen 200 mg or selected 'neither' with a typical pain duration of less than (\<) 6 hours, if left untreated.

Percentage of Participants Who Correctly Select to Use or Correctly De-select Not to Use Ibuprofen 600 mg IR/ER Study Medication Excluding Those Classified as Missed Opportunity
Day 1

Participants as correct selectors included all participants who selected Ibuprofen 600 mg IR/ER medication with the last episode of pain of \>=6 hours, if left untreated. Participants as correct de-selectors included all participants who either selected Ibuprofen 200 mg or selected 'neither' with a typical pain duration of \<6 hours, if left untreated. Participants were classified as "missed opportunity" cases when they selected the Ibuprofen 200 mg IR medication with their typical duration of pain \>=6 hours.

Percentage of Participants Who Select to Use Ibuprofen 600 mg IR/ER Medication With a Typical Pain Duration of Less Than (<) 6 Hours
Day 1

Percentage of participants with correct selection of Ibuprofen 600 mg IR/ER medication with a typical duration of pain \<6 hours were reported in this outcome measure.

Percentage of Participants Who Select to Use Ibuprofen 200 mg IR Medication With a Typical Pain Duration of Greater Than or Equal to (>=) 6 Hours
Day 1

Percentage of participants with selection of Ibuprofen 200 mg IR medication with a typical duration of pain \>=6 hours were reported in this outcome measure. These participants were classified as ''missed opportunity'' cases.

Percentage of Participants With the Use of Study Medication For Greater Than (>) 10 Days With an Average Daily Dose of Greater Than (>) 1600 mg
Day 1 up to Day 30

Percentage of participants with the use of study medication for \>10 days with an average daily dose of \>1600 mg were reported in this outcome measure.

Percentage of Participants With the Use of Study Medication For Less Than or Equal to (<=) 10 Days and Use More Than 20 Tablets With an Average Daily Dose of Greater Than (>) 1600 mg
Day 1 up to Day 30

Percentage of participants who used the study medication for \<=10 days and used more than 20 tablets with an average daily dose of \>1600 mg were reported in this outcome measure.

Secondary Endpoints

Average Daily Dose Among Excessive Users
Day 1 up to Day 30
Number of Dosing Days Among Inappropriate Users
Day 1 up to Day 30
Number of Pain Episodes Treated With Single Dose or Multiple Dose Among Inappropriate Users
Day 1 up to Day 30
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Ibuprofen 600 mg Immediate Release/Extended Release CapletEXPERIMENTAL -

Interventions

NameTypeDescription
Ibuprofen 600 mg Immediate Release/Extended Release CapletDRUGIbuprofen 600 mg Immediate Release/Extended Release Caplet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
Unlock Study Design Details

Eligibility Criteria

Age Range12 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites18

Inclusion Criteria: * at least 12 years of age * use of at least 5 doses per month of over-the-counter pain relievers over the past 3 months * provide written informed consent (subjects 12-\<18 years of age provide a written assent and parent/guardian will provide written informed consent) * capabl...

Countries:United States
Unlock Eligibility Criteria